Anavex Life Sciences Corp (AVXL)

[BAR123]

Question for theboard. What happens if we hit our 2 primary endpoints on the AD trial and only one of the secondary endpoints, that being safety. What do we think the FDA or Australian ( FDA ) would do? The other secondary that I am speaking about is :
CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) [ Time Frame: 48 weeks ]
Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

Any thoughts on what might happen as we approach the regulatory agencies?
Thanks